NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs
Policy / Regulatory

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors
CompanyDrug

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide
CompanyDrug

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule
CompanyDeals

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule

Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy
CompanyDeals

Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy

Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma
CompanyDeals

Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
CompanyDrug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer
CompanyDrug

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer

CompanyDrug

Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977
CompanyDrug

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China
CompanyDrug

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies
CompanyDeals

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies